Increased Plasma Levels of Lipoprotein(a) and the Risk of Idiopathic and Recurrent Venous Thromboembolism

American Journal of Medicine

Volumn 115, Issue 8, 2003, Pages 601-605

  Marcucci, Rossella ^a   Liotta, Agatina Alessandrello ^a   Cellai, Anna Paola ^a   Rogolino, Angela ^a   Gori, Anna Maria ^a   Giusti, Betti ^a   Poli, Daniela ^a   Fedi, Sandra ^a   Abbate, Rosanna ^a   Prisco, Domenico ^a  

^a Clin Medica Generale e Cardiologia   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN; BLOOD CLOTTING FACTOR 5; CARDIOLIPIN ANTIBODY; HOMOCYSTEINE; LIPOPROTEIN A; PROTHROMBIN;

ADULT; AGED; ANAMNESIS; ARTICLE; CARDIOVASCULAR RISK; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HEMOSTASIS; HUMAN; IDIOPATHIC DISEASE; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; METHODOLOGY; MULTIVARIATE ANALYSIS; PATIENT; PRIORITY JOURNAL; RECURRENT DISEASE; RISK ASSESSMENT; RISK FACTOR; VENOUS THROMBOEMBOLISM;

EID: 0345167959     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjmed.2003.06.005     Document Type: Article

References (37)

1. Nordstrom M., Lindblad B., Berqvist D., Kjellstrom T. A prospective study of the incidence of deep vein thrombosis within a defined urban population. J Intern Med. 232:1992;155-160.
2. Hansson P.O., Werlin L., Tibblin G., Eriksson H. Deep vein thrombosis and pulmonary embolism in the general population. Arch Intern Med. 157:1997;1665-1670.
3. Lensing A.W.A., Prandoni P., Prins M.H., Buller H.R. Deep vein thrombosis. Lancet. 353:1999;479-485.
4. Dahlback B. Blood coagulation. Lancet. 355:2000;1627-1635.
5. Den Heijer M., Rosendaal F.R., Blom H.J., et al. Hyperhomocysteinemia and venous thrombosis: a meta-analysis. Thromb Haemost. 80:1998;874-877.
6. Zenker G., Koltringer P., Bonè G., et al. Lp(a) as a strong indicator for cerebrovascular disease. Stroke. 17:1986;942-945.
7. Albers J.J., Hazzard W.R. Immunochemical quantification of human plasma Lp(a) lipoprotein. Lipids. 9:1974;15-26.
8. Berg K., Dahlen G., Frick M.H. Lp(a) lipoprotein and pre-beta-1 lipoprotein in patients with coronary heart disease. Clin Genet. 6:1974;230-235.
9. Seed M., Hopplichler F., Reaveley D., et al. Relation of serum Lp(a) concentration and apoLp(a) phenotype to coronary heart disease in patients with familial hypercholesterolemia. N Engl J Med. 322:1990;1494-1499.
10. Misirli H., Somay G., Ozbal N., Yasar Erenoglu N. Relation of lipid and Lp(a) to ischemic stroke. J Clin Neurosci. 2:2002;127-132.
11. Hobbs H., White A.L. Lp(a): intrigues and insights. Curr Opin Lipidol. 10:1999;225-236.
12. McLean J.W., Tomlinson J.E., Kuang W.-J., et al. cDNA sequence of human apoLp(a) is homologous to plasminogen. Nature. 300:1987;132-137.
13. Von Depka M., Nowak-Gottl U., Eisert R., et al. Increased Lp(a) levels as an independent risk factor for venous thromboembolism. Blood. 96:2000;3364-3368.
14. Nowak-Gottl U., Junker R., Hartmeier M., et al. Increased Lp(a) is an important risk factor for venous thromboembolism in childhood. Circulation. 100:1999;743-748.
15. Marz W., Trommlitz M., Scharrer I., Gross W. ApoLp(a) concentrations are not related to the risk of venous thrombosis. Blood Coagul Fibrinol. 2:1991;595-599.
16. Lippi G., Bassi A., Brocco G., et al. Lp(a) concentration is not associated with venous thromboembolism in a case control study. Haematologica. 84:1999;726-729.
17. McColl M.D., Sattar N., Ellison J., et al. Lp(a), cholesterol and triglycerides in women with venous thromboembolism. Blood Coagul Fibrinol. 11:2000;225-229.
18. Seriolo B., Accardo S., Fasciolo D., et al. Lipoproteins, anticardiolipin antibodies and thrombotic events in rheumatoid arthritis. Clin Exp Rheumatol. 14:1996;593-599.
19. Fujita T., Saito E., Ohi H., et al. Lipoprotein(a) predicts the risk of thrombogenic complications in nephrotic syndrome [letter]. Nephron. 61:1992;122.
20. Alaupovic P., Fesmire J.D., Hunnighake D., et al. The effect of aggressive and moderate lowering of LDL-cholesterol and low-dose anticoagulation on plasma lipids, apolipoproteins and lipoprotein families in post coronary artery bypass graft trial. Atherosclerosis. 146:1999;369-372.
21. Marcucci R., Prisco D., Brunelli T., et al. Tissue factor and homocysteine levels in ischemic heart disease are associated with angiographically documented clinical recurrences after coronary angioplasty. Thromb Haemost. 83:2000;826-832.
22. Stein J.H., Rosenson R.S. Lp(a) excess and coronary heart disease. Arch Intern Med. 157:1997;1170-1176.
23. Haijar K.A., Nachman R.L. The role of Lp(a) in atherogenesis and thrombosis. Annu Rev Med. 47:1996;423-442.
24. Rader D.J.H., Hoeg J.M., Brewer H.B. Jr. Quantification of plasma apolipoproteins in the primary and secondary prevention of coronary artery disease. Ann Intern Med. 120:1994;1012-1025.
25. Ridker P.M., Hennekens C.H., Stampfer M.J. A prospective study of lipoprotein(a) and the risk of myocardial infarction. JAMA. 270:1993;2195-2199.
26. Nowak-Gottl U., Junker R., Kreuz W., et al. Risk of recurrent venous thrombosis in children with combined prothrombotic risk factors. Blood. 97:2001;858-862.
27. Maeda S., Abe A., Seishima M., et al. Transient changes of serum Lp(a) as an acute phase protein. Atherosclerosis. 78:1989;145-150.
28. Korte W., Greiner J., Feldges A., Riesen W.F. Increased Lp(a) levels are not a steady prothrombotic defect [letter]. Blood. 98:2001;1993-1994.
29. Lee Y.H., Choi S.J., Ji J.D., et al. Lp(a) and lipids in relation to inflammation in rheumatoid arthritis. Clin Rheumatol. 19:2000;324-325.
30. Kario K., Matsuo T., Kobayashi H., et al. High Lp(a) levels in chronic hemodialysis patients are closely related to the acute phase reaction. Thromb Haemost. 74:1995;1020-1024.
31. Gurbuz O., Ozdemir Y., Cosar C.B., Kural G. Lp(a) in Behcet's disease as an indicator of disease activity and in thrombotic complications. Eur J Ophthalmol. 11:2001;62-65.
32. Noma A., Abe A., Maeda S., et al. Lp(a): an acute-phase reactant? Chem Phys Lipids. 67-68:1994;411-417.
33. Ramharack R., Barkalow D., Spahr M.A. Dominant negative effect of TGF-beta1 and TNF-alpha on basal and IL6 induced Lp(a) and apoLp(a) mRNA expression in primary monkey hepatocyte cultures. Arterioscler Thromb Vasc Biol. 18:1998;984-990.
34. Harpel P.C., Hermann A., Zhang X., et al. Lp(a), plasmin modulation, and atherogenesis. Thromb Haemost. 74:1995;382-386.
35. Estelles A., Cano A., Falcò C., et al. Lp(a) levels and isoforms and fibrinolytic activity in postmenopause: influence of hormone replacement therapy. Thromb Haemost. 81:1999;104-110.
36. Tuck C.H., Holleran S., Berglund L. Hormone regulation of Lp(a) levels: effects of estrogen replacement therapy on Lp(a) and acute phase reactants in postmenopausal women. Arterioscler Thromb Vasc Biol. 17:1997;1822-1829.
37. Falcò C., Tormo G., Estelles A., et al. Fibrinolysis and Lp(a) in women with coronary artery disease. Influence of hormone replacement therapy. Haematologica. 86:2001;92-98.